Skip to main content
Top
Published in: International Journal of Clinical Oncology 6/2013

01-12-2013 | Editorial

Current status of treatment strategy for elderly patients with gastric cancer

Author: Atsushi Nashimoto

Published in: International Journal of Clinical Oncology | Issue 6/2013

Login to get access

Excerpt

The World Health Organization (WHO) has defined the chronological age of 65 or older as a definition of “elderly” or older person, and defined the former aged for people from 65 to 74 years, the latter aged for people from 75 to 84 years, and the super aged for people 85 years and more. In industrialized countries, life expectancy has increased consistently over the past decades. Life expectancy (male/female) in Japan was 18.86/23.89 years for those 65 years old, 11.58/15.38 years for those 75 years old, and 6.18/8.30 years for those 85 years old by the complete life table in 2010, respectively. In Japan the population peaked in 2004 and has been decreasing recently. However, the number of people 65 years old and over is increasing continuously, being 23.0 % in 2010; further, 20 % of gastric cancer patients in Japan are more than 80 years old. According to the aging society, the current status of treatment strategy for elderly patients with gastric cancer is discussed. …
Literature
1.
go back to reference Endo S, Dousei T, Yoshikawa Y et al (2012) Prognosis of gastric carcinoma patients aged 85 years or older who underwent surgery or who received best supportive care only. Int J Clin Oncol. doi:10.1007/s10147-012-0482-9 Endo S, Dousei T, Yoshikawa Y et al (2012) Prognosis of gastric carcinoma patients aged 85 years or older who underwent surgery or who received best supportive care only. Int J Clin Oncol. doi:10.​1007/​s10147-012-0482-9
Metadata
Title
Current status of treatment strategy for elderly patients with gastric cancer
Author
Atsushi Nashimoto
Publication date
01-12-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0498-1

Other articles of this Issue 6/2013

International Journal of Clinical Oncology 6/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine